Filing Flows › Spero Therapeutics (SPRO) › Q1 2025
Spero Therapeutics (SPRO) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Spero Therapeutics (SPRO) reported revenue of $5.9M for the first quarter 2025 (Q1 2025), -37% from a year earlier and -61% from the quarter before. Operating margin was -250.8%, net loss $13.9M (236.1% of revenue).
Spero Therapeutics, Q1 2025: revenue $5.9M (-37% year over year), operating margin -250.8%, net loss $13.9M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.9M | -61% | -37% |
| Operating profit | −$14.7M | — | — |
| Net earnings | −$13.9M | — | — |
| Operating cash flow | −$4.0M | — | — |
What changed
Revenue was $5.9M in Q1 2025, down 37% year over year and down 61% from the previous quarter. Collaboration Revenue Related Party was the largest line at 87% of revenue. Grant Revenue lost $4.3M year over year (down 85%), 127% of the total change.
Operating costs exceeded revenue by $14.7M, an operating margin of -250.8%. Total costs fell 11% while revenue fell 37%. The fastest-growing cost line was General & admin (+15%). The quarter ended with a net loss of $13.9M, narrower than the previous quarter's $20.9M loss.
Operating cash flow was −$4.0M. Non-cash charges added back $1.6M of share-based compensation. Working capital and other items added $8.3M.
Questions
What was Spero Therapeutics' revenue in the first quarter 2025?
Spero Therapeutics (SPRO) reported revenue of $5.9M for the first quarter 2025 (Q1 2025), -37% from a year earlier and -61% from the quarter before.
Was Spero Therapeutics profitable in the first quarter 2025?
Operating loss was $14.7M (-250.8% of revenue) and net loss $13.9M.
Source: Spero Therapeutics 10-Q on SEC EDGAR.